A gene therapy approach to eliminate HIV-1-infected cells.
The ideal therapy for HIV infection requires a method to eliminate all HIV-harboring cells in the infected individual. The authors are developing an HIV-specific promoter to drive the expression of suicide genes that would induce cell death specifically in HIV-infected cells. The authors constructed a promoter that is 100-fold more responsive to the HIV transcriptional activator, Tat, than cellular transcription factors, using a plasmid expressing luciferase under the control of the mutated LTR promoter.
Department of Biomedical Sciences, University of the Pacific, Arthur A. Dugoni School of Dentistry, San Francisco 94115, USA.
Senait
S
Gebremedhin
Amy
A
Au
Krystyna
K
Konopka
Matthew
M
Milnes
Nejat
N
Düzgüneş
D016923:Cell Death / Q000235:genetics; D015967:Gene Expression Regulation, Viral / Q000235:genetics; D041722:Genes, Transgenic, Suicide / Q000235:genetics; D015756:Genes, tat / Q000235:genetics; D015316:Genetic Therapy / Q000379:methods*; D015658:HIV Infections / Q000628:therapy*; D016325:HIV Long Terminal Repeat / Q000235:genetics; D015497:HIV-1 / Q000235:genetics*; D006367:HeLa Cells; D006801:Humans; D008156:Luciferases; D049408:Luminescent Agents; D009154:Mutation / Q000235:genetics; D010957:Plasmids / Q000235:genetics; D011401:Promoter Regions, Genetic / Q000235:genetics; D013601:T-Lymphocytes / Q000821:virology*; D014162:Transfection
D049408:Luminescent Agents; D008156:Luciferases